CGH
CELG

Crossmark Global Holdings’s Celgene Corp CELG Stock Holding History

Crossmark Global Holdings’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-72,215
Closed -$7.17M – 1476
2019
Q3 		$7.17M Sell
72,215
-3,095
-4% -$294K 0.21% 122
2019
Q2 		$6.96M Sell
75,310
-5,256
-7% -$499K 0.2% 127
2019
Q1 		$7.6M Sell
80,566
-4,617
-5% -$404K 0.22% 124
2018
Q4 		$5.46M Sell
85,183
-1,576
-2% -$116K 0.17% 156
2018
Q3 		$7.76M Sell
86,759
-3,299
-4% -$292K 0.2% 129
2018
Q2 		$7.15M Sell
90,058
-3,406
-4% -$283K 0.19% 131
2018
Q1 		$8.34M Sell
93,464
-4,042
-4% -$388K 0.22% 119
2017
Q4 		$10.2M Sell
97,506
-3,314
-3% -$374K 0.24% 97
2017
Q3 		$14.7M Buy
+100,820
New +$13.7M 0.38% 48
2016
Q3 		$14.7M Buy
+100,820
New +$10.9M 0.38% 48

Other funds holding CELG

FP
Factorial Partners Mt. Kisco, New York $138M AUM 25.59% 1-Year Est. Return
HCM
Howard Capital Management Roswell, Georgia $6.11B AUM 33.56% 1-Year Est. Return
PCMC
Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return

Crossmark Global Holdings's CELG Position: Q4 2019 in Review

Crossmark Global Holdings sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 72,215 shares — an estimated $7.17M sold.

Crossmark Global Holdings first reported a position in CELG in Q3 2016 and held it in 10 quarters. The position peaked at $14.7M in Q3 2017. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Crossmark Global Holdings reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Crossmark Global Holdings sold 72,215 Celgene Corp shares in Q4 2019, an estimated $7.17M.
  • Crossmark Global Holdings first reported a position in Celgene Corp in Q3 2016 and held it in 10 quarters.
  • Crossmark Global Holdings's Celgene Corp position peaked at $14.7M in Q3 2017.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Crossmark Global Holdings's 13F filing for Q4 2019, filed 6 Feb 2020.